[{"id":"01c9490b-851c-40e3-bd81-bb560b20b9de","acronym":"","url":"https://clinicaltrials.gov/study/NCT04777084","created_at":"2021-03-02T12:52:16.287Z","updated_at":"2024-07-02T16:35:25.092Z","phase":"Phase 1","brief_title":"The Efficacy and Safety of the Bispecific Anti-PD-1/PD-L1 Antibody IBI318 Combined With Lenvatinib in NSCLC.","source_id_and_acronym":"NCT04777084","lead_sponsor":"Hunan Province Tumor Hospital","biomarkers":" ALK • ROS1","pipe":" | ","alterations":" PD-L1 expression • EGFR T790M • PD-L1 negative • ALK fusion • ROS1 fusion • ALK-ROS1 fusion","tags":["ALK • ROS1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • EGFR T790M • PD-L1 negative • ALK fusion • ROS1 fusion • ALK-ROS1 fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lenvima (lenvatinib) • reozalimab (IBI318)"],"overall_status":"Recruiting","enrollment":" Enrollment 120","initiation":"Initiation: 08/01/2021","start_date":" 08/01/2021","primary_txt":" Primary completion: 12/30/2024","primary_completion_date":" 12/30/2024","study_txt":" Completion: 12/25/2025","study_completion_date":" 12/25/2025","last_update_posted":"2023-12-27"}]